18 completed, 10 terminated, 1 active not recruiting, 1 withdrawn. 30 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 30 | Completed 18, Terminated 10, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Terminated 2, Withdrawn 1 |
Follow Small Intestine Lymphoma: new trials by email Literature Review of Small Intestine Lymphoma trials Research Report on Small Intestine Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 30 | 2013-10-08 | 2026-06-25 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Ipilimumab and Local Radiation for Selected Solid Tumors Ipilimumab, Radiation therapy - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Stanford University | 3 | 2013-02-01 | 2024-01-24 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies fludarabine phosphate, methoxyamine, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 20 | 2011-05-01 | 2015-08-13 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2010-06-01 | 2014-11-07 |
| Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma azacitidine, bortezomib, Correlative studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Pierluigi Porcu | 8 | 2010-05-01 | 2013-12-03 |
| Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma lenalidomide, vorinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | City of Hope Medical Center | 30 | 2010-05-01 | 2010-12-09 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma 2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2009-07-01 | 2014-01-07 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma DI-Leu16-IL2 immunocytokine, rituximab, flow cytometry - Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 9 | 2008-03-17 | 2026-10-23 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction vorinostat, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2007-06-01 | 2014-02-24 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma bevacizumab, cediranib maleate - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 57 | 2007-05-01 | 2014-02-19 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer cetuximab, erlotinib hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Completed | National Cancer Institute (NCI) | 43 | 2007-01-01 | 2015-09-30 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma gemcitabine hydrochloride, triapine - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-09-30 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma tanespimycin, belinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2006-05-01 | 2013-05-16 |
Showing 20 of 30. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (26) · Intraocular Lymphoma (25) · Leukemia, Lymphocytic, Chronic, B-Cell (25) · Lymphoma, B-Cell, Marginal Zone (25) · Lymphoma, Follicular (25) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (25) · Burkitt Lymphoma (24) · Lymphoma, Mantle-Cell (24) · Lymphoma, Large-Cell, Anaplastic (23) · Lymphoma, Non-Hodgkin (23) · Mycosis Fungoides (23) · Sezary Syndrome (23) · Waldenstrom Macroglobulinemia (23) · Lymphoma, Large-Cell, Immunoblastic (22) · Immunoblastic Lymphadenopathy (21)
Neoplasms (30) · Neoplasms by Histologic Type (30) · Hematologic Diseases (28) · Hemic and Lymphatic Diseases (28) · Immune System Diseases (28) · Immunoproliferative Disorders (28) · Lymphatic Diseases (28) · Lymphoma (28) · Lymphoproliferative Disorders (28) · Leukemia (27) · Leukemia, Lymphoid (27) · Lymphoma, B-Cell (27) · Neoplasms by Site (27) · Disease Attributes (26) · Pathologic Processes (26)
Rituximab (5) · Lenalidomide (3) · tanespimycin (3) · Bortezomib (2) · CTLA-4 Antigen (2) · Doxorubicin (2) · Etoposide (2) · Ipilimumab (2) · Irinotecan (2) · Peripheral Blood Stem Cell Transplantation (2) · Vincristine (2) · Vorinostat (2) · fludarabine phosphate (2) · 2'-fluoro-5-ethylarabinosyluracil (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)
National Cancer Institute (NCI) (17) · City of Hope Medical Center (3) · Fred Hutchinson Cancer Center (2) · Case Comprehensive Cancer Center (1) · Mayo Clinic (1) · Morphotek (1) · Northwestern University (1) · Pierluigi Porcu (1) · Stanford University (1) · University of Chicago (1) · Wake Forest University Health Sciences (1)
United States (29) · Canada (3) · Italy (1)
Ramesh Ramanathan (2) · Adam Petrich, MD (1) · Ajay Gopal (1) · David Hong (1) · David Maloney (1) · Elizabeth Budde (1) · George A. Fisher, MD, PhD (1) · George Wilding (1) · Grzegorz Nowakowski (1) · Kristie Blum (1) · Laura Goff (1) · Leslie Popplewell (1) · Lisa McGregor (1) · Mark Ratain (1) · Maryam Fouladi (1)
PMID 23256542, PMID 23393050, PMID 27118452, PMID 29292843, PMID 32499241, PMID 34515338, PMID 40720747
U01CA062491 (4), U01CA062487 (3), U01CA097452 (3), U01CA099168 (3), P30CA015083 (2), P30CA015704 (2), P50CA107399 (2), U01CA062505 (2), U01CA076576 (2), N01CM62208 (1), P01CA044991 (1), P01CA078902 (1), P30CA012197 (1), P30CA014520 (1), P30CA014599 (1)